David Allen Reardon MD

Clinical Trials

• Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) Start of enrollment: 2004 Oct 13

  Completed

  Phase 2

• Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) Start of enrollment: 2004 Jan 01

  Completed

  Phase 1, Phase 2

• Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma Start of enrollment: 2004 Jul 01

  Completed

  Phase 1

• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma Start of enrollment: 2005 May 01

  Completed

  Phase 2

• Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma Start of enrollment: 2005 Jul 01

  Completed

  Phase 1

• AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2006 Oct 01

  Unknown status

  Phase 1, Phase 2

• Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM Start of enrollment: 2007 Sep 01

  Completed

  Phase 2

• Ph I SU011248 + Irinotecan in Treatment of Pts w MG Start of enrollment: 2008 Mar 01

  Completed

  Phase 1

• Ph II Bevacizumab + Etoposide for Pts w Recurrent MG Start of enrollment: 2007 Mar 01

  Completed

  Phase 2

• Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas Start of enrollment: 2005 Jan 01

  Completed

  Phase 1

• Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM Start of enrollment: 2005 Feb 01

  Completed

  Phase 1

• Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan Start of enrollment: 2008 Apr 01

  Completed

  Phase 2

• Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma Start of enrollment: 2002 Oct 01

  Completed

  Phase 2

• Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy Start of enrollment: 2008 Jun 01

  Terminated

  Phase 3

• Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide Start of enrollment: 2005 Nov 01

  Completed

  Phase 2

• Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) Start of enrollment: 2007 Feb 01

  Completed

  Phase 2

• Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme Start of enrollment: 2007 Apr 01

  Completed

  Phase 2

• Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2009 Jul 10

  Completed

  Phase 1, Phase 2

• Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2009 May 01

  Unknown status

  Phase 2

• A Panobinostat Presurgery Start of enrollment: 2010 Apr 01

  Withdrawn

  Phase 2

• Amgen 386 for Recurrent Glioblastoma Start of enrollment: 2010 Dec 01

  Completed

  Phase 1, Phase 2

• A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01

  Completed

  Phase 2

• A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2013 Jul 18

  Completed

  Phase 1, Phase 2

• A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07

  COMPLETED

  PHASE3

• Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

  COMPLETED

  PHASE1, PHASE2

• A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Start of enrollment: 2015 Jan 01

  Completed

  Phase 1, Phase 2

• An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

  ACTIVE_NOT_RECRUITING

  PHASE2

• Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM Start of enrollment: 2018 May 21

  ACTIVE_NOT_RECRUITING

  PHASE2

• Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Start of enrollment: 2018 Sep 28

  COMPLETED

  PHASE2

• ASP8374 + Cemiplimab in Recurrent Glioma Start of enrollment: 2022 Mar 09

  ACTIVE_NOT_RECRUITING

  PHASE1

• First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma Start of enrollment: 2020 Jul 13

  COMPLETED

  PHASE1, PHASE2

  Roles: Contact

• Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

  RECRUITING

  PHASE1

  Roles: Principal Investigator, Contact

• SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) Start of enrollment: 2021 Nov 18

  Active, not recruiting

  Phase 2

  Roles: Contact

• Study of DSP-0390 in Patients with Recurrent High-Grade Glioma Start of enrollment: 2021 Sep 08

  ACTIVE_NOT_RECRUITING

  EARLY_PHASE1

  Roles: Contact

• Join now to see all